
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is expected to have a positive outlook due to their promising assets in solid tumor treatment, projected peak revenues of $6.8B from their leading BTK inhibitor, and upcoming catalysts such as potential approvals and data updates. Additionally, their deprioritization of early-stage programs and updated valuation, along with highly anticipated updates on their CDK4i, GPC3, and B7-H4 programs, further reinforce a strong outlook for the company.
Bears say
BeOne Medicines is a holding company with a negative outlook due to concerns over sustainability issues such as green manufacturing and drug pricing, as well as a lack of diversity in the management team and clinical trial data transparency. Despite being a leading player in the CLL market and having a strong revenue stream, the company's potential for long-term value creation and upside is uncertain due to the potential challenges in their pipeline and R&D execution. These factors could hinder the company's growth and profitability, leading to a negative outlook for the stock.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares